B lymphocyte depletion therapy with rituximab in rheumatoid arthritis

Rheumatic Disease Clinics of North America

Volumn 30, Issue 2, 2004, Pages 393-403

  Edwards, J C W ^a   Leandro, M J ^a   Cambridge, G ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB; SALAZOSULFAPYRIDINE;

ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE HEMOLYTIC ANEMIA; B LYMPHOCYTE; BREAST CARCINOMA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DERMATOMYOSITIS; DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; DRUG SAFETY; FEVER; GLOMERULONEPHRITIS; GOODPASTURE SYNDROME; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY AMYLOIDOSIS; LOWER RESPIRATORY TRACT INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MONOTHERAPY; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NEUROPATHY; OVARY CARCINOMA; PANCYTOPENIA; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; THROMBOCYTOPENIA; WEGENER GRANULOMATOSIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; HUMANS; LYMPHOCYTE DEPLETION; TREATMENT OUTCOME;

EID: 2542490265     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2004.01.006     Document Type: Review

References (25)

1. Edwards J.C.W., Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology. 40:2001;205-211
2. Leandro M.J., Edwards J.C.W., Cambridge G. Clinical outcome in 22 patients with RA treated with B lymphocyte depletion. Ann Rheum Dis. 61:2002;1-5
3. De Vita S., Zaja F., Sacco S., De Candia A., Fanin R., Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum. 46:2002;2029-2033
4. Edwards J.C.W., Leandro M.J., Cambridge G. B lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders. Biochem Soc Trans. 30:2002;824-828
5. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Close D.R., Stevens R.M., et al. Efficacy and safety of rituximab: a randomized, placebo-controlled trial in patients with RA. Arthritis Rheum. 46:2002;S197
6. Edwards J.C.W., Cambridge G. Rheumatoid arthritis: the predictable effect of small immune complexes in which antibody is also antigen. Br J Rheumatol. 37:1998;126-130
7. Edwards J.C.W., Cambridge G., Abrahams V.M. Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology. 97:1999;1868-1876
8. Waaler E. On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles. Acta Pathol Microbiol Scand. 17:1940;172-188
9. Mannik M., Nardella F.A. IgG rheumatoid factors and self-association of these antibodies. Clin Rheum Dis. 11:1985;551-572
10. Nardella F.A., Dayer J.M., Roelke M., Krane S.M., Mannik M. Self-associating IgG rheumatoid factors stimulate monocytes to release prostaglandins and mononuclear cell factor that stimulates collagenase and prostaglandin production by synovial cells. Rheumatol Int. 3:1983;183-186
11. Chang Y.H., Pearson C.M. Pathogenesis of adjuvant arthritis in rats. Arthritis Rheum. 21:1978;169-170
12. van Boxel J.A., Paget S.A. Predominantly T cell infiltrate in rheumatoid synovial membranes. N Engl J Med. 293:1975;517-520
13. Stastny P. Association of the B cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med. 298:1978;869-872
14. Firestein G.S., Zvaifler N.J. How important are T cells in chronic rheumatoid synovitis? Arthritis Rheum. 33:1990;768-773
15. Edwards J.C.W., Cambridge G. Is rheumatoid arthritis a failure of B cell death in synovium? Ann Rheum Dis. 54:1995;696-700
16. Abrahams V.M., Cambridge G., Edwards J.C.W. Induction of tumour necrosis factor alpha production by human monocytes: a key role for FcγRIIIa in rheumatoid arthritis. Arthritis Rheum. 43:2002;608-616
17. Bhatia A., Blades S., Cambridge G., Edwards J.C.W. Differential distribution of FcγRIIIa in normal human tissues and co-localization with DAF and fibrillin-1: implications for immunological microenviroments. Immunology. 94:1998;656-663
18. Matsumoto I., Maccioni M., Lee D.M., Maurice M., Simmons B., Brenner M., et al. How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease. Nat Immunol. 3:2002;360-365
19. Roosnek E., Lanzavecchia A. Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells. J Exp Med. 173:1991;487-489
20. McLaughlin P. Rituximab: perspective on single agent experience, and future directions in combination trials. Crit Rev Oncol Hematol. 40:2001;3-16
21. Gopal A.K., Press O.W. Clinical applications of anti-CD20 antibodies. J Lab Clin Med. 134:1999;445-450
22. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., et al. Depletion of B cells in vivo by a chimaeric mouse human monoclonal antibody to CD20. Blood. 83:1994;435-445
23. Cambridge G., Leandro M.J., Edwards J.C.W., Ehrenstein M.R., Salden M., Bodman-Smith M., et al. Serological changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 48:2003;2146-2154
24. Leandro M.J., Edwards J.C.W., Cambridge G., Ehrenstein M.R., Isenberg D.A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 46:2002;2673-2677
25. Halldorsdottir H.D., Jonsson T., Thorsteinsson J., Valdimarsson H. A prospective study on the incidence of rheumatoid arthritis among people with persistent increase of rheumatoid factor. Ann Rheum Dis. 59:2000;149-151